Apr 16, 2013 by Brian Orelli, PhDPowerful Cholesterol-Lowering Drugs on Their WayHowever, these newcomers won't replace statins.
Apr 16, 2013 by Brian Orelli, PhD3 Ways Your Pet Can Make You a Better InvestorFido and Snowball offer investment ideas and more.
Apr 16, 2013 by Brian Orelli, PhDJohnson & Johnson Stock Is on the MendAfter being stagnant for a few years, Johnson & Johnson stock is turning around thanks to solid growth.
Apr 16, 2013 by Brian Orelli, PhDFDA Makes Obesity Drug Available to More AmericansVIVUS' Qsymia now available in retail pharmacies.
Apr 15, 2013 by Brian Orelli, PhDRoyalty Pharma Willing to Pay More for Elan, Depending on Investor DemandsPurchase price tied to Dutch auction.
Apr 15, 2013 by Brian Orelli, PhDThe FDA Helps Investors Breathe WellGlaxoSmithKline and Theravance's COPD drug Breo gets a marginally positive review from the Food and Drug Administration.
Apr 15, 2013 by Brian Orelli, PhDObama's Budget Hurts Seniors, Helps HospitalsHowever, it's only for rich seniors, and it's only a temporary fix for hospitals.
Apr 15, 2013 by Brian Orelli, PhDMore Than an Obesity Drug CompanyArena Pharmaceuticals presses on as it waits to launch its obesity drug Belviq.
Apr 11, 2013 by Brian Orelli, PhDFDA Throws ACADIA a Juicy BoneAfter meeting with the Food and Drug Administration, only one phase 3 trial will be required.
Apr 10, 2013 by Brian Orelli, PhDOral Hepatitis C Cure on Its WayGilead Sciences asks the FDA to approve sofosbuvir.
Apr 10, 2013 by Brian Orelli, PhDFDA's Breakthrough Therapy Designation More Bling Than BiteCompanies say, "the implications of Breakthrough Therapy Designation cannot be determined at this time."
Mar 31, 2013 by Brian Orelli, PhDUnderstanding Why Cancer Vaccines FailThe immune system attacks the injection site.
Mar 30, 2013 by Brian Orelli, PhDGet Paid to Lose WeightEmployers might offer cash prizes to save money later.
Mar 29, 2013 by Brian Orelli, PhDThis Pharma's Dividend Is Safe for NowEli Lilly's free cash flow plunged, but it had a cushion built in.
Mar 28, 2013 by Brian Orelli, PhDUp 76% Overnight With Room to RunRepros' Androxal drug passes its first clinical trial, but not without some hiccups.
Mar 28, 2013 by Brian Orelli, PhD3 Reasons Investors Are Scared of Biotech StocksThere's more than one way to see monster drops.
Mar 27, 2013 by Brian Orelli, PhDHow's That Long-Term Biotech Investment Looking?An investment in Arena five years ago doesn't look that great.
Mar 26, 2013 by Brian Orelli, PhDA Silver Lining in a Sea of RedZIOPHARM down big after palifosfamide fails, but it could be worse.
Mar 25, 2013 by Brian Orelli, PhDJ&J Recalls Diabetes Blood Glucose MetersOneTouch Verio IQ meters in U.S. shut off at high readings.
